<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856371</url>
  </required_header>
  <id_info>
    <org_study_id>CYH33-G103</org_study_id>
    <nct_id>NCT04856371</nct_id>
  </id_info>
  <brief_title>Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haihe Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haihe Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, phase Ib study designed to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and preliminary efficacy of CYH33 administered orally in&#xD;
      combination with standard-of-care ET ± CDK4/6 inhibitor therapies for the treatment of&#xD;
      locally advanced, recurrent or metastatic hormone-receptor positive (HR+), human epidermal&#xD;
      growth factor receptor 2 negative (HER2-) breast cancer. Patients will be enrolled in two&#xD;
      stages, including dose exploration phase (Stage 1) and dose expansion phase (Stage 2) of each&#xD;
      cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence rate of DLT in the first cycle (of 28 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>30 months</time_frame>
    <description>Type, incidence, duration, severity and seriousness of adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy-ORR</measure>
    <time_frame>30 months</time_frame>
    <description>Tumor objective response rate (ORR) assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy-CBR</measure>
    <time_frame>30 months</time_frame>
    <description>Clinical benefit rate (CBR) assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy-PFS</measure>
    <time_frame>30 months</time_frame>
    <description>Progression Free Survival (PFS) assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - AUC</measure>
    <time_frame>20 months</time_frame>
    <description>Measure the variation of concentration in blood plasma as a function of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - C trough</measure>
    <time_frame>20 months</time_frame>
    <description>Measure the minimum (trough) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - Cmax</measure>
    <time_frame>20 months</time_frame>
    <description>Measure the maximum (peak) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - Tmax</measure>
    <time_frame>20 months</time_frame>
    <description>Measure of time to reach maximum (peak) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - CL/F</measure>
    <time_frame>20 months</time_frame>
    <description>Measure apparent total clearance(s) from plasma after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measures - Vz/F</measure>
    <time_frame>20 months</time_frame>
    <description>Measure apparent volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess downstream effects of PI3K pathway inhibition on blood glucose</measure>
    <time_frame>20 months</time_frame>
    <description>Pre- and post-treatment of blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess downstream effects of PI3K pathway inhibition on C peptide</measure>
    <time_frame>20 months</time_frame>
    <description>Pre- and post-treatment of C peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the changes of biomarker-PIK3CA</measure>
    <time_frame>20 months</time_frame>
    <description>Pre- and post-treatment PIK3CA changes in ctDNA samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the changes of biomarker-PTEN</measure>
    <time_frame>20 months</time_frame>
    <description>Pre- and post-treatment PTEN changes in ctDNA samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the changes of biomarker-KRAS</measure>
    <time_frame>20 months</time_frame>
    <description>Pre- and post-treatment KRAS changes in ctDNA samples.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CYH33 + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CYH33 in combination with a standard fixed dose of fulvestrant 500 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYH33 + fulvestrant + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CYH33 in combination with standard fixed dose of fulvestrant (500 mg) and palbociclib (125 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYH33 + letrozole + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive CYH33 in combination with standard fixed dose of letrozole (2.5 mg) and palbociclib (125 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYH33</intervention_name>
    <description>Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.</description>
    <arm_group_label>CYH33 + fulvestrant</arm_group_label>
    <arm_group_label>CYH33 + fulvestrant + palbociclib</arm_group_label>
    <arm_group_label>CYH33 + letrozole + palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.</description>
    <arm_group_label>CYH33 + fulvestrant</arm_group_label>
    <arm_group_label>CYH33 + fulvestrant + palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.</description>
    <arm_group_label>CYH33 + letrozole + palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.</description>
    <arm_group_label>CYH33 + fulvestrant + palbociclib</arm_group_label>
    <arm_group_label>CYH33 + letrozole + palbociclib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Provide informed consent voluntarily.&#xD;
&#xD;
          2. Male and female patients ≥ 18 years of age.&#xD;
&#xD;
          3. Patient must have a histologically or cytologically documented locally advanced,&#xD;
             recurrent or metastatic breast cancer.&#xD;
&#xD;
          4. In case of women, both premenopausal and postmenopausal patients can be enrolled in&#xD;
             the study.&#xD;
&#xD;
          5. Confirmed diagnosis of HR+, HER2- breast cancer.&#xD;
&#xD;
          6. For Stage 1 dose exploration phase, patients with or without PIK3CA mutation may be&#xD;
             enrolled; For Stage 2 dose expansion phase, patients with PIK3CA mutations are&#xD;
             required.&#xD;
&#xD;
          7. Patient must have evidence of disease radiological progression after previous&#xD;
             endocrine therapy, or other systemic therapy.&#xD;
&#xD;
          8. Patient has measurable disease per RECIST v1.1.&#xD;
&#xD;
          9. ECOG ≤ 1.&#xD;
&#xD;
         10. Patient must have adequate organ and bone marrow function.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Previously received any anticancer therapy within 28 days or 5 times of half-lives&#xD;
             prior to the first dose of the study treatment.&#xD;
&#xD;
          2. Previously received treatment with any PI3Kα inhibitor, AKT inhibitor, or mTOR&#xD;
             inhibitor.&#xD;
&#xD;
          3. Radical radiation therapy within 4 weeks prior to the first dose of the study&#xD;
             treatment.&#xD;
&#xD;
          4. Patient with an established diagnosis of diabetes mellitus.&#xD;
&#xD;
          5. Any other concurrent disease with potential risk of insulin resistance or current use&#xD;
             of medication with potential risk of insulin resistance.&#xD;
&#xD;
          6. Patient with clinically significant cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Yuan, MD</last_name>
    <phone>86 13820384005</phone>
    <email>yong.yuan@haihepharma.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIK3CA Mutant</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

